Nexgel Inc(NXGL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 18 at 4:10 PM ET (Korea 9/19 05:10)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.72 | Insider Own | 14.08% | Shs Outstand | 9.7M | Perf Week | -8.69% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | 76.6% | Insider Trans | -1.98% | Shs Float | 8.4M | Perf Month | -34.19% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -0.24 | Inst Own | 6.03% | Short Float | 4.73% | Perf Quarter | -53.04% |
| Income | -0.01B | P/S | 0.27 | EPS this Y | -147.37% | Inst Trans | 2.76% | Short Ratio | 0.52 | Perf Half Y | -65.86% |
| Sales | 0.01B | P/B | 0.52 | EPS next 5Y | 49.14% | ROA | -34.21% | Short Interest | 0.40M | Perf YTD | -83.49% |
| Book/sh | 0.51 | P/C | 1.91 | EPS past 3/5Y | 23.44% -77.47% | ROE | -128.59% | 52W High | -90.8% ($2.89) | Perf Year | -89.74% |
| Cash/sh | 0.14 | P/FCF | - | Sales past 3/5Y | 77.33% 76.12% | ROIC | -53.83% | 52W Low | 10.75% ($0.24) | Perf 3Y | -87.92% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -78.48% | Gross Margin | 34.73% | Volatility(W/M) | 10.61% 10.49% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 0.79 | Sales Y/Y TTM | 3.38% | Oper. Margin | -44.77% | ATR (14) | 0.04 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.27 | EPS Q/Q | -364.1% | Profit Margin | -51.26% | RSI (14) | 35.38 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.43 | Sales Q/Q | 27.81% | SMA20 | -16.36% ($0.32) | Beta | 0.79 | Target Price | $2 |
| Payout | - | Debt/Eq | 1.51 | Earnings | 2026/8/14 | SMA50 | -31.14% ($0.39) | Rel Volume | 0.2 | Prev Close | $0.26 |
| Employees | 19 | LT Debt/Eq | 1.32 | EPS/Sales Surpr. | -233.33% -14.58% | SMA200 | -68.36% ($0.85) | Avg Volume(3M) | 0.76M | Price | $0.27 |
| IPO | 2021/12/22 | Option/Short | No/Yes | Trades | 457 | Volume | 151,526 | Change | 2.63% |
Company
NXGL is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🩹 NexGel (NXGL) is a U.S. micro-cap medical device and consumer healthcare company that manufactures high-performance hydrogels using proprietary electron beam technology. It operates both its own branded OTC products and contract manufacturing, and is currently expanding into the regenerative medicine field through its recent acquisition of Celularity assets.
Over the past 1 year, on the lower side
91% below its 1-year high.
NXGL has weak earning power
-44.77% of revenue is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -147.4% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -87.9% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 6.0%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
DFAS 0.00%
VXF 0.00%It ranks #4 in the industry
Based on market cap of $3M.
NXGL $3M PER -
ISRG $139B PER 45.1
BDX $49B PER 54.6
MDLN $42B PER 37.1
FAQ
What kind of company is NXGL?
NXGL belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of NXGL?
The market cap of NXGL is approximately $3M, ranking 5,783 within its sector.
What is the 52-week high and low for NXGL?
NXGL has recorded a 52-week high of $2.89 and a low of $0.24.
